LncRNA-MIAT Increased in Patients with Coronary Atherosclerotic Heart Disease.

BACKGROUND:To study the expression and clinical significance of long noncoding RNA- (lncRNA-) MIAT in patients with coronary atherosclerotic heart disease (CAD). METHODS:Serum MIAT, interleukin-6 (IL-6), and tumor necrosis factor-α (TNF-α) in 106 CAD patients and 89 healthy donors were detected. Correlations between serum MIAT and serum IL-6 and TNF-α were analyzed. Risk factors for patients with CAD were analyzed by multiple factor analysis. RESULTS:Compared with healthy donors, serum lncRNA-MIAT was significantly increased in CAD patients. Serum MIAT was positively correlated with serum IL-6 and TNF-α in CAD. Multivariate analysis found that hypertension (OR (95% CI) = 3.471 (2.180-4.091), P=0.011), diabetes (OR (95% CI) = 3.682 (1.698-4.897), P=0.003), HDL-C (OR (95% CI) = 3.372 (1.760-6.920), P=0.001), and serum MIAT expression (OR (95% CI) = 2.687 (1.683-7.468), P=0.001) were independent risk factors for CAD. CONCLUSIONS:Serum lncRNA-MIAT in CAD patients was significantly increased, which may be a potential marker for diagnosis and prognosis of CAD.